Wed, 26th Apr 2023 07:38
(Sharecast News) - GSK first quarter profits and revenue both beat expectations driven by its shingles and meningitis treatments, among others.
The company posted revenue of £7bn against expectations of £6.5bnm according to company-compiled estimates. Adjusted operating profit rose 8% to £2.1bn as GSK also maintained full-year guidance.
Its shingles vaccine, Shingrix, generated sales of £833m, beating estimates of £829m.
Reporting by Frank Prenesti for Sharecast.com
(Sharecast News) - Volatile moves in GSK's share price are likely to persist in the near term as a result of ongoing Zantac-related litigation, but th...
(Alliance News) - GSK PLC on Tuesday said it has taken the first steps to seek appeal of a ruling by the Delaware Superior Court in regard to its disc...
(Alliance News) - Stock prices in London opened higher on Tuesday, after a difficult day for markets on Monday amid the EU election fallout.
(Alliance News) - The FTSE 100 in London was called to open higher on Tuesday, after data showed that unemployment in the UK unexpectedly rose.
(Sharecast News) - GSK has started the process of appealing a recent decision by the Delaware Superior Court regarding the ongoing Zantac, or ranitidi...
Glaxosmithkline (GSK)